膜蛋白降解对红细胞膜脂流动性的影响

目的与方法：本文通过实验的方法,采用胰蛋白酶降解红细胞膜蛋白,研究了膜蛋白降解对红细胞膜脂流动性的影响。结果：随着胰蛋白酶作用浓度的升高,经马来酰亚胺（ＭＳＬ）标记的膜蛋白ＥＳＲ谱表现为弱强固定比（Ｓ／Ｗ）趋于上升,ＤＰＨ标记的膜脂荧光偏振度（Ｐ）值上升,且呈现出明显的量效关系;结论;这意味着由于胰蛋白酶的作用,降解了红细胞膜蛋白,使得膜蛋白结构趋于收缩,最终导致了膜脂流动性的降低。     

大鼠大脑皮质胆囊收缩素受体的体外结合分析法研究

用Ｂｏｌｔｏｎ－Ｈｕｎｔｅｒ试剂联结法标记胆囊收缩素（ＣＣＫ８）,得１２５Ｉ－ＢＨ－ＣＣＫ８,其比放射性为３．４ＴＢｑ／ｍｍｏｌ,放射化学纯度大于９６％。取其与自制的大鼠大脑皮质细胞膜进行受体放射分析,发现标记配体与大鼠大脑皮质ＣＣＫ受体的结合具有温度和时间依赖性,可饱和性,可逆性及特异性。经Ｓｃａｔｃｈａｒｄ分析获大鼠大脑皮质细胞膜ＣＣＫ受体Ｋｄ值为１．０９８ｎｍｏｌ／Ｌ,Ｂｍａｘ为１９７．５ｆｍｏｌ／ｍｇ蛋白。     

BCL-2、p53蛋白在胆管癌组织中的表达

目的 研究ＢＣＬ－２蛋白、Ｐ５３蛋白表达与胆管癌预后的关系。方法 应用免疫组化研究４０例胆管癌组织中ＢＣＬ－２蛋白、ｐ５３蛋白表达及其与胆管癌组织类型及术后生存期的关系。结果 胆管癌组织中ＢＣ 白和Ｐ５３蛋白表达旨也生率分别为５５％和４７．５％;ＢＣＬ－２蛋白与Ｐ５３蛋白的表达呈负相关,低分化癌Ｐ５３蛋白阳性率高于高分化癌,高分化癌ＢＣＬ－２蛋白阳性率高于低分化癌;ＢＣＬ－２蛋白表达高或Ｐ５３蛋白     

谷胱甘肽转移酶π在胃癌的表达及与预后的关系

目的 探讨光甘肽转移酶π（ＧＳＴ－π）与胃癌的分型、分期及预后的关系。方法 应用鼠抗人ＧＳＴ－π单克隆抗体对８０例胃癌进行免疫组化研究。结果 ＧＳＴ－π在癌旁正常组织中的是性表达与生存期有统计学意义（Ｐ〈０．０５）;在癌组织中的表达强度与平均生存期有关（Ｐ〈０．０５）。ＧＳＴ－π表达与临床分期及胃癌组织分化程度无关（Ｐ〉０．０５）。不同生存年段中ＧＳＴ－π的表达也无统计学差异（Ｐ〉０．０５）。结论     

重度颅脑损伤病人康复期智力和记忆力及情感变化

目的探讨重度颅脑损伤病人康复期智力、记忆力及情感等方面的改变。②方法根据格拉斯哥昏迷指数（ＧＣＳ）所规定的等级,对４１例重度颅脑损伤病人进行智力、记忆力能力测验,并与我国常模比较。③结果康复优良组病人的操作智商、语言商数均在正常范围。重残组７５．０％的病人语言商数明显降低,３６．８％轻残组病人和１００％重残病人操作智商降低。④结论严重颅脑损伤病人存在着智力、记忆力和情感障碍,重度残疾病人以操作智商降低为主,康复优良病人常出现智力与记忆力缺陷。     

湖北麻城农村妇女自杀情况的流行病学调查分析

选择湖北麻城市属５个乡８４个村为调查单位,共调查１９９２～１９９４年女性自杀死亡病例１９９例（调查率９１７０％）．经对获取资料进行的流行病学分析,结果提示：１９９２～１９９４年麻城妇女自杀死亡率分别是６４４９／１０万、８５．００／１０万和７８．１４／１０万;其中,２０～２９岁,３０～３９岁以及６０～６９岁为死亡人数高峰组;自杀方式以服毒者居多。     

Comparison of observer reliability in assessing alveolar bone changes from color-coded with subtraction radiographs

OBJECTIVES: To assess intra- and interobserver agreement on marginal changes in periodontal bone from color-coded compared with subtraction radiographs. METHODS: Sequential radiographs from patients undergoing periodontal treatment were acquired using direct digital intra-oral radiography. Fifty-one pairs of color-coded and subtraction radiographs were produced and evaluated twice by six dentists for changes in marginal bone. Intra- and interobserver agreement were calculated. RESULTS: Intra-observer agreement was significantly higher for the color-coded radiographs (P < 0.05). Interobserver agreement was significantly higher for color-coded radiographs at the second (P < 0.001) but not the first (P = 0.34) evaluation. CONCLUSIONS: Color coding of radiographic differences by means of image addition may be a feasible alternative to the subtraction technique for evaluating periodontal bone changes.     

Free fatty acids impair hepatic insulin extraction in vivo

Hyperinsulinemia is a common finding in obesity and results from insulin hypersecretion and impaired hepatic insulin extraction. In vitro studies have shown that free fatty acids (FFAs), which are often elevated in obesity, can impair insulin binding and degradation in isolated rat hepatocytes. To investigate whether FFAs impair hepatic insulin extraction (E(H)) in vivo, either saline (SAL) or 10% Intralipid (0.03 ml x kg(-1) x min(-1)) plus heparin (0.44 U x kg(-1) x min(-1)) (IH) was infused into normal dogs to elevate FFA levels. Insulin was infused intraportally at 18 pmol x kg(-1) x min(-1) for 150 min (period A, high insulin dose), and then at 2.4 pmol x kg(-1) x min(-1) for another 150 min (period B, low insulin dose). After the low portal insulin dose, additional insulin was infused peripherally at 8.4 pmol x kg(-1) x min(-1) for 120 min (period C) to assess the clearance of insulin from the peripheral plasma. In 16 paired experiments, FFA levels were 1,085 +/- 167, 1,491 +/- 240, 1,159 +/- 221 micromol/l (IH) and 221 +/- 44, 329 +/- 72, 176 +/- 44 micromol/l (SAL) in periods A, B, and C, respectively. Peripheral insulin levels were greater with IH (P < 0.001) than with SAL in all periods (1,620 +/- 114, 126 +/- 12, 1,050 +/- 72 pmol/l for IH vs. 1,344 +/- 168, 96 +/- 4.2, 882 +/- 60 pmol/l for SAL). Glucose clearance was impaired by IH in all periods (P < 0.05), whereas glucose production was slightly increased by IH during period B. Peripheral insulin clearance (Cl) and E(H) were calculated from the insulin infusion rate and insulin concentration data in each period by taking into account the nonlinearity of insulin kinetics. Cl was lower (P < 0.01) with IH (9.6 +/- 0.6, 12.0 +/- 0.9, 10.2 +/- 0.6 ml x kg(-1) x min(-1)) than with SAL (11.2 +/- 1, 13.6 +/- 0.7, 11.9 +/- 0.9 ml x kg(-1) x min(-1)) in periods A, B, and C. E(H) was also lower (P < 0.05) with IH (25 +/- 4, 40 +/- 5, 32 +/- 5%) than with SAL (30 +/- 2.8, 47 +/- 3, 38 +/- 3%). We conclude that FFAs can impair hepatic insulin extraction in vivo at high and low insulin levels, an effect that may contribute to the peripheral hyperinsulinemia of obesity.     

细支气管肺泡癌的CT表现

目的：回顾性分析细支气管肺泡癌（ＢＡＣ）的ＣＴ表现：方法：４２例经病理证实的ＢＡＣ,根据ＣＴ表现分为结节型,实变型和多结节型,分别为２３,１６和３例;结合献资料分析各型肺泡癌的ＣＴ征角。结果;结节型ＢＡＣ主要表现为：肺外周（９５．７％）,分叶（６９．６％）,空泡征或细支气管气象（６５．２％）,密度不均（６５．２％）,胸膜牵引（６０．９％）和毛玻璃影（５２．２％）;     

Effects of pre- and postnatal cysteamine exposure on renal function in the rat

The safety of cysteamine after renal transplantation and during pregnancy is an important issue, since girls with cystinosis are in better health on cysteamine therapy and thus more likely to become pregnant. In the first study, cysteamine was given to pregnant rats on days 6.5–18.5 post conception in oral doses of 0, 37.5, 75, 100, and 150 mg/kg per day. The dams were sacrificed on day 20.5, the fetal kidneys removed and prepared for histological examination. In the second study, cysteamine was given to dams on days 6.5–19.5 post conception in oral doses of 0, 37.5, 50, and 75 mg/kg per day. Dams were allowed to give birth naturally and pups were given cysteamine on days 4–21 to yield the same oral doses of cysteamine given to the dam. Renal function was evaluated on day 35. Histological examination of fetal kidneys revealed no changes even in kidneys from fetuses with growth retardation and malformations. Furthermore, there were no alterations in renal function in offspring on day 35. These findings demonstrate that cysteamine therapy does not affect renal development in the rat. Further investigations will be required to prove whether cysteamine therapy has the potential to affect renal development in the human. Received: 25 September 1998 / Revised: 17 November 1998 / Accepted: 13 December 1998